HEB : Summary for Hemispherx BioPharma, Inc. Comm - Yahoo Finance

U.S. Markets open in 3 hrs 4 mins

Hemispherx Biopharma, Inc. (HEB)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.49+0.02 (+5.27%)
At close: 4:01PM EST
People also watch
GNBTCVMBCRXCTICVICL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.46
Open0.46
Bid0.00 x
Ask0.00 x
Day's Range0.46 - 0.52
52 Week Range0.39 - 2.64
Volume297,302
Avg. Volume223,763
Market Cap12.67M
Beta-0.36
PE Ratio (TTM)-1.07
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals19 days ago

    $1M deal: Hemispherx plans to sell stock, warrants

    Hemispherx Biopharma Inc. entered into definitive agreements with several institutional investors under which the Philadelphia biotechnology company will receive gross proceeds of about $1 million through a sale of its common stock. Last week, Hemispherx announced that an order of newly manufactured Ampligen for sale using an Early Access Program to benefit patients suffering with chronic fatigue syndrome and pancreatic cancer in Europe had been shipped. In a letter to shareholders earlier this week, Hemispherx CEO Thomas K. Equels said the company expects to continue its discussions with the Food and Drug Administration to “identify a path forward” for Ampligen as a treatment for chronic fatigue syndrome.

  • GlobeNewswire20 days ago

    Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering

    PHILADELPHIA, Feb. 02, 2017-- Hemispherx Biopharma, Inc., announced today that it has entered into definitive agreements with several institutional investors for an offering of shares of common stock with ...

  • GlobeNewswire27 days ago

    Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe

    PHILADELPHIA, Jan. 26, 2017-- Hemispherx Biopharma announced today that an order of newly manufactured rintatolimod for sale utilizing the Early Access Program in Europe has been shipped with receipt confirmed ...